698 related articles for article (PubMed ID: 15024716)
1. Gastrointestinal stromal tumors: overview of pathologic features, molecular biology, and therapy with imatinib mesylate.
Koh JS; Trent J; Chen L; El-Naggar A; Hunt K; Pollock R; Zhang W
Histol Histopathol; 2004 Apr; 19(2):565-74. PubMed ID: 15024716
[TBL] [Abstract][Full Text] [Related]
2. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
Croom KF; Perry CM
Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
[TBL] [Abstract][Full Text] [Related]
3. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors.
Chen LL; Trent JC; Wu EF; Fuller GN; Ramdas L; Zhang W; Raymond AK; Prieto VG; Oyedeji CO; Hunt KK; Pollock RE; Feig BW; Hayes KJ; Choi H; Macapinlac HA; Hittelman W; Velasco MA; Patel S; Burgess MA; Benjamin RS; Frazier ML
Cancer Res; 2004 Sep; 64(17):5913-9. PubMed ID: 15342366
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review.
Miettinen M; El-Rifai W; H L Sobin L; Lasota J
Hum Pathol; 2002 May; 33(5):478-83. PubMed ID: 12094372
[TBL] [Abstract][Full Text] [Related]
5. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.
Demetri GD
Semin Oncol; 2001 Oct; 28(5 Suppl 17):19-26. PubMed ID: 11740803
[TBL] [Abstract][Full Text] [Related]
6. Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KIT.
Bauer S; Corless CL; Heinrich MC; Dirsch O; Antoch G; Kanja J; Seeber S; Schütte J
Cancer Chemother Pharmacol; 2003 Mar; 51(3):261-5. PubMed ID: 12655446
[TBL] [Abstract][Full Text] [Related]
7. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.
Heinrich MC; Corless CL; Demetri GD; Blanke CD; von Mehren M; Joensuu H; McGreevey LS; Chen CJ; Van den Abbeele AD; Druker BJ; Kiese B; Eisenberg B; Roberts PJ; Singer S; Fletcher CD; Silberman S; Dimitrijevic S; Fletcher JA
J Clin Oncol; 2003 Dec; 21(23):4342-9. PubMed ID: 14645423
[TBL] [Abstract][Full Text] [Related]
8. Gastrointestinal stromal tumors (GIST): a model for molecule-based diagnosis and treatment of solid tumors.
Kitamura Y; Hirota S; Nishida T
Cancer Sci; 2003 Apr; 94(4):315-20. PubMed ID: 12824897
[TBL] [Abstract][Full Text] [Related]
9. Activating mutations in c-KIT and PDGFRalpha are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genes.
Burger H; den Bakker MA; Kros JM; van Tol H; de Bruin AM; Oosterhuis W; van den Ingh HF; van der Harst E; de Schipper HP; Wiemer EA; Nooter K
Cancer Biol Ther; 2005 Nov; 4(11):1270-4. PubMed ID: 16294026
[TBL] [Abstract][Full Text] [Related]
10. Gastrointestinal stromal tumors (GIST): C-kit mutations, CD117 expression, differential diagnosis and targeted cancer therapy with Imatinib.
de Silva CM; Reid R
Pathol Oncol Res; 2003; 9(1):13-9. PubMed ID: 12704441
[TBL] [Abstract][Full Text] [Related]
11. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors.
Hirota S; Ohashi A; Nishida T; Isozaki K; Kinoshita K; Shinomura Y; Kitamura Y
Gastroenterology; 2003 Sep; 125(3):660-7. PubMed ID: 12949711
[TBL] [Abstract][Full Text] [Related]
12. Extracellular domain c-kit mutation with duplication of Ser501Ala502 found in gastrointestinal stromal tumors is more imatinib- and nilotinib-sensitive than that with duplication of Ala502Tyr503.
Liu NN; Ohkouchi M; Hashikura Y; Kajimoto N; Matsuda I; Isozaki K; Toh Y; Takahashi T; Nishida T; Hirota S
Lab Invest; 2013 May; 93(5):502-7. PubMed ID: 23459373
[TBL] [Abstract][Full Text] [Related]
13. Management of malignant gastrointestinal stromal tumours.
Joensuu H; Fletcher C; Dimitrijevic S; Silberman S; Roberts P; Demetri G
Lancet Oncol; 2002 Nov; 3(11):655-64. PubMed ID: 12424067
[TBL] [Abstract][Full Text] [Related]
14. Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571).
Demetri GD
Eur J Cancer; 2002 Sep; 38 Suppl 5():S52-9. PubMed ID: 12528773
[TBL] [Abstract][Full Text] [Related]
15. Gastrointestinal stromal tumors.
Antonescu C
Curr Top Microbiol Immunol; 2012; 355():41-57. PubMed ID: 22015552
[TBL] [Abstract][Full Text] [Related]
16. The role of KIT in the management of patients with gastrointestinal stromal tumors.
Hornick JL; Fletcher CD
Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861
[TBL] [Abstract][Full Text] [Related]
17. The reappraisal of gastrointestinal stromal tumors: from Stout to the KIT revolution.
Dei Tos AP
Virchows Arch; 2003 May; 442(5):421-8. PubMed ID: 12759750
[TBL] [Abstract][Full Text] [Related]
18. Imatinib inhibits various types of activating mutant kit found in gastrointestinal stromal tumors.
Chen H; Isozaki K; Kinoshita K; Ohashi A; Shinomura Y; Matsuzawa Y; Kitamura Y; Hirota S
Int J Cancer; 2003 May; 105(1):130-5. PubMed ID: 12672043
[TBL] [Abstract][Full Text] [Related]
19. Biology of gastrointestinal stromal tumors: KIT mutations and beyond.
Duensing A; Heinrich MC; Fletcher CD; Fletcher JA
Cancer Invest; 2004; 22(1):106-16. PubMed ID: 15069768
[TBL] [Abstract][Full Text] [Related]
20. Update on the biology and therapy of gastrointestinal stromal tumors.
D'Amato G; Steinert DM; McAuliffe JC; Trent JC
Cancer Control; 2005; 12(1):44-56. PubMed ID: 15668652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
